Total assets $ 6,740,140 $ 12,212,609
=========== ===========
LIABILITIES AND STOCKHOLDERS'
EQUITY
Current liabilities:
Accounts payable $ 3,127,348 $ 1,359,898
Accrued expenses 934,372 1,152,460
Deferred underwriting commissions -- 2,911,260
Warrant liability 4,803 141,276
----------- -----------
Total current liabilities 4,066,523 5,564,894
----------- -----------
Total liabilities 4,066,523 5,564,894
----------- -----------
Stockholders' equity:
Common Stock, $0.001 par value;
500,000,000 shares authorized at
September 30, 2024 and December
31, 2023 and 4,292,455 and
264,537 issued and outstanding
at September 30, 2024 and
December 31, 2023, respectively 4,292 265
Additional paid-in-capital 41,449,244 32,114,552
Accumulated deficit (38,779,919) (25,467,102)
----------- -----------
Total stockholders' equity 2,673,617 6,647,715
----------- -----------
Total liabilities and stockholders'
equity $ 6,740,140 $ 12,212,609
=========== ===========
View source version on businesswire.com: https://www.businesswire.com/news/home/20241108038521/en/
CONTACT: Chester Zygmont, III
Chief Financial Officer
Email: czygmont@revbiosciences.com
(END) Dow Jones Newswires
November 08, 2024 16:15 ET (21:15 GMT)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.